Striatal Dopamine Induced ERK Phosphorylation Is Altered in Mouse Models of Monogenic Dystonia
- 17 January 2021
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 36 (5) , 1147-1157
Abstract
Background: Similar to some monogenic forms of dystonia, levodopa‐induced dyskinesia is a hyperkinetic movement disorder with abnormal nigrostriatal dopaminergic neurotransmission. Molecularly, it is characterized by hyper‐induction of phosphorylation of extracellular signal‐related kinase in response to dopamine in medium spiny neurons of the direct pathway.Objectives: The objective of this study was to determine if mouse models of monogenic dystonia exhibit molecular features of levodopa‐induced dyskinesia.Methods: Western blotting and quantitative immunofluorescence was used to assay baseline and/or dopamine‐induced levels of the phosphorylated kinase in the striatum in mouse models of DYT1, DYT6, and DYT25 expressing a reporter in dopamine D1 receptor‐expressing projection neurons. Cyclic adenosine monophosphate (cAMP) immunoassay and adenylyl cyclase activity assays were also performed.Results: In DYT1 and DYT6 models, blocking dopamine reuptake with cocaine leads to enhanced extracellular signal‐related kinase phosphorylation in dorsomedial striatal medium spiny neurons in the direct pathway, which is abolished by pretreatment with the N‐methyl‐d‐aspartate antagonist MK‐801. Phosphorylation is decreased in a model of DYT25. Levels of basal and stimulated cAMP and adenylyl cyclase activity were normal in the DYT1 and DYT6 mice and decreased in the DYT25 mice. Oxotremorine induced increased abnormal movements in the DYT1 knock‐in mice.Conclusions: The increased dopamine induction of extracellular signal‐related kinase phosphorylation in 2 genetic types of dystonia, similar to what occurs in levodopa‐induced dyskinesia, and its decrease in a third, suggests that abnormal signal transduction in response to dopamine in the postsynaptic nigrostriatal pathway might be a point of convergence for dystonia and other hyperkinetic movement disorders, potentially offering common therapeutic targets. © 2021 International Parkinson and Movement Disorder SocietyKeywords
Funding Information
- National Institute of Neurological Disorders and Stroke (NS081282, NS107883)
- National Institutes of Health (DA036596)
This publication has 90 references indexed in Scilit:
- Cholinergic Dysfunction Alters Synaptic Integration between Thalamostriatal and Corticostriatal Inputs in DYT1 DystoniaJournal of Neuroscience, 2012
- The Complex of G Protein Regulator RGS9-2 and Gβ 5 Controls Sensitization and Signaling Kinetics of Type 5 Adenylyl Cyclase in the StriatumScience Signaling, 2012
- Alteration of Striatal Dopaminergic Neurotransmission in a Mouse Model of DYT11 Myoclonus-DystoniaPLOS ONE, 2012
- An anticholinergic reverses motor control and corticostriatal LTD deficits in Dyt1 ΔGAG knock-in miceBehavioural Brain Research, 2012
- Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic designGene Therapy, 2011
- Enhanced striatal cholinergic neuronal activity mediatesl-DOPA–induced dyskinesia in parkinsonian miceProceedings of the National Academy of Sciences, 2010
- Decreased striatal dopamine receptor binding in primary focal dystonia: A D2 or D3 defect?Movement Disorders, 2010
- Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (ΔE) TorsinA in transgenic miceNeurobiology of Disease, 2010
- Function of dopamine transporter is compromised in DYT1 transgenic animal modelin vivoJournal of Neurochemistry, 2010
- The Cu–Zn superoxide dismutase (SOD1) inhibits ERK phosphorylation by muscarinic receptor modulation in rat pituitary GH3 cellsBiochemical and Biophysical Research Communications, 2008